MX2009010611A - Enlazadores biespecificos, especificos para especies. - Google Patents
Enlazadores biespecificos, especificos para especies.Info
- Publication number
- MX2009010611A MX2009010611A MX2009010611A MX2009010611A MX2009010611A MX 2009010611 A MX2009010611 A MX 2009010611A MX 2009010611 A MX2009010611 A MX 2009010611A MX 2009010611 A MX2009010611 A MX 2009010611A MX 2009010611 A MX2009010611 A MX 2009010611A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- human
- species
- cross
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Abstract
La presente invención se refiere a un polipéptido que comprende un primer dominio de enlace humano capaz de enlazarse a un epítope de cadena CD3 (epsilon) de humano y de primate no chimpancé y un segundo dominio de enlace capaz de enlazarse a EGFR, Her2/neu o IgE de un humano y/o un primate no chimpancé así como a un proceso para la producción del polipéptido mencionado. La invención se refiere además a ácidos nucleicos que codifican para el polipéptido, a vectores que comprenden el mismo y a células huésped que comprenden el vector. En otro aspecto, la invención proporciona una composición farmacéutica que comprende el polipéptido mencionado y usos médicos del polipéptido.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07006990 | 2007-04-03 | ||
EP07006988 | 2007-04-03 | ||
US91366807P | 2007-04-24 | 2007-04-24 | |
EP07020641 | 2007-10-22 | ||
EP07020640 | 2007-10-22 | ||
EP07020646 | 2007-10-22 | ||
EP08004741 | 2008-03-13 | ||
PCT/EP2008/002663 WO2008119566A2 (en) | 2007-04-03 | 2008-04-03 | Cross-species-specific bispecific binders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010611A true MX2009010611A (es) | 2010-03-26 |
Family
ID=39609399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010611A MX2009010611A (es) | 2007-04-03 | 2008-04-03 | Enlazadores biespecificos, especificos para especies. |
Country Status (14)
Country | Link |
---|---|
US (4) | US20100183615A1 (es) |
EP (1) | EP2155788B1 (es) |
JP (1) | JP6016747B2 (es) |
KR (1) | KR101626988B1 (es) |
CN (1) | CN101675077B (es) |
AU (1) | AU2008234019B2 (es) |
CA (1) | CA2682626A1 (es) |
HK (1) | HK1141299A1 (es) |
HR (1) | HRP20120759T1 (es) |
IL (1) | IL201338A (es) |
MX (1) | MX2009010611A (es) |
PL (1) | PL2155788T3 (es) |
WO (1) | WO2008119566A2 (es) |
ZA (1) | ZA200907116B (es) |
Families Citing this family (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10100098B2 (en) * | 2006-12-13 | 2018-10-16 | Stelis Biopharma Private Limited | Insulin production methods and proinsulin constructs |
JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
NZ591134A (en) | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa) |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
US9260522B2 (en) * | 2008-10-01 | 2016-02-16 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
RU2547600C2 (ru) | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
JP2011026294A (ja) * | 2009-06-26 | 2011-02-10 | Canon Inc | 化合物 |
US8993715B2 (en) * | 2009-07-06 | 2015-03-31 | Canon Kabushiki Kaisha | Labeled protein and method for obtaining the same |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
TWI629357B (zh) * | 2009-10-02 | 2018-07-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種特異性的PSMAxCD3雙特異性單鏈抗體 |
TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
EP2377888A1 (en) * | 2010-04-07 | 2011-10-19 | Corimmun GmbH | Fusion protein |
CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
EP2637670B2 (en) | 2010-11-10 | 2024-03-13 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
CA2833019A1 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
US8846042B2 (en) * | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
UA117072C2 (uk) | 2011-05-21 | 2018-06-11 | Макродженікс, Інк. | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським |
RU2605390C2 (ru) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
WO2013048243A1 (en) * | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
AU2012350429A1 (en) | 2011-12-09 | 2013-07-11 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies |
AU2012368189B2 (en) * | 2011-12-29 | 2017-08-31 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
CA2876133C (en) * | 2012-06-07 | 2017-06-06 | Duke University | Human bispecific egfrviii antibody engaging molecules |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
CN104780940B (zh) | 2012-11-06 | 2017-11-07 | 拜耳制药股份公司 | 用于双特异性t细胞衔接体(bites)的制剂 |
WO2014079000A1 (en) * | 2012-11-21 | 2014-05-30 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
DK2961771T3 (da) | 2013-02-26 | 2020-03-02 | Roche Glycart Ag | Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA |
EP3444278A1 (en) | 2013-02-26 | 2019-02-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
KR20230073341A (ko) * | 2013-07-05 | 2023-05-25 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
PL3192812T3 (pl) * | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
WO2015105888A1 (en) * | 2014-01-07 | 2015-07-16 | Bioatla, Llc | Proteins targeting orthologs |
RS61129B1 (sr) | 2014-02-28 | 2020-12-31 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
LT3149480T (lt) | 2014-05-30 | 2019-04-25 | Amgen Research (Munich) Gmbh | B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas |
BR112017001579A2 (pt) | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
WO2016020309A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
RS61134B1 (sr) | 2014-11-20 | 2020-12-31 | Hoffmann La Roche | Kombinovana terapija bispecifičnim antigen vezujućim molekulima koji aktiviraju t ćelije za cd3 i folatni receptor 1 (folr1), i antagonistima vezivanja ose pd-1 |
PL3689140T3 (pl) * | 2014-11-24 | 2022-09-05 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
SG11201704449VA (en) | 2014-12-05 | 2017-06-29 | Genentech Inc | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
CA2977687C (en) | 2015-02-24 | 2024-02-13 | Hwai Wen Chang | Conditionally active proteins |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CN104829729B (zh) * | 2015-04-03 | 2018-08-14 | 复旦大学 | 一种携带抗Her2/CD3双特异性功能蛋白的人T细胞制备 |
JP2018520642A (ja) * | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
EP3302555A4 (en) * | 2015-05-29 | 2018-07-11 | Amphivena Therapeutics, Inc. | Methods of using bispecific cd33 and cd3 binding proteins |
IL256079B2 (en) | 2015-06-16 | 2024-01-01 | Genentech Inc | Human antibodies with improved affinity to FCRH5 - and methods of use |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | 抗cd3抗体及び使用方法 |
US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
KR20180042271A (ko) | 2015-08-03 | 2018-04-25 | 잉맵 에스에이알엘 | Bcma에 대응하는 단일클론 항체 |
AU2016308567B2 (en) | 2015-08-17 | 2022-10-27 | Janssen Biotech, Inc. | Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof |
WO2017040344A2 (en) | 2015-08-28 | 2017-03-09 | Amunix Operating Inc. | Chimeric polypeptide assembly and methods of making and using the same |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子 |
MX2018004988A (es) | 2015-10-23 | 2018-11-09 | Merus Nv | Moleculas de union que inhibe el crecimiento de cancer. |
EA201891084A1 (ru) | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
CN115920030A (zh) | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
WO2017142928A1 (en) | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド (エイチケイ) リミテッド | 多重特異性Fab融合タンパクおよびその使用 |
PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
SG11201808979UA (en) | 2016-04-15 | 2018-11-29 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
SG11201810883TA (en) | 2016-06-07 | 2019-01-30 | Macrogenics Inc | Combination therapy |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
KR20190053835A (ko) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
MX2019004621A (es) | 2016-11-02 | 2019-11-28 | Engmab Sarl | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. |
JP2020503260A (ja) | 2016-11-15 | 2020-01-30 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体による処置のための投与 |
JP7254699B2 (ja) | 2016-12-21 | 2023-04-10 | テネオバイオ, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics Inc | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
BR112019020508A2 (pt) | 2017-03-31 | 2020-08-04 | Merus N.V. | anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1 |
CA3060190A1 (en) * | 2017-04-24 | 2018-11-01 | Glenmark Pharmaceuticals S.A. | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
KR20200018498A (ko) | 2017-06-20 | 2020-02-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
JP2020530028A (ja) | 2017-08-09 | 2020-10-15 | メルス ナムローゼ フェンノートシャップ | EGFR及びcMETに結合する抗体 |
AU2018314236A1 (en) | 2017-08-11 | 2020-03-19 | Apterna Limited | RNA aptamers against transferrin receptor (TfR) |
US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
MX2020003087A (es) | 2017-09-21 | 2020-08-17 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-cd3epsilon novedosos. |
US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック, インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
AU2019281358A1 (en) | 2018-06-03 | 2021-01-07 | Lamkap Bio Beta Ltd. | Bispecific antibodies against CEACAM5 and CD47 |
JP2021535142A (ja) | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Cd3/c20二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
CA3111462A1 (en) | 2018-09-11 | 2020-03-19 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Improved anti-flt3 antigen binding proteins |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
AU2019370339A1 (en) | 2018-11-01 | 2021-06-10 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
US20220041719A1 (en) | 2018-12-05 | 2022-02-10 | Morphosys Ag | Multispecific antigen-binding molecules |
CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
JP2022535060A (ja) | 2019-06-07 | 2022-08-04 | アムジエン・インコーポレーテツド | 選択的に切断可能なリンカーを有する二重特異性結合構築物 |
AR119746A1 (es) | 2019-06-14 | 2022-01-05 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
US20230136228A1 (en) | 2019-09-18 | 2023-05-04 | Lamkap Bio Alpha AG | Bispecific antibodies against ceacam5 and cd3 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
CA3163950A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
MX2022008654A (es) | 2020-01-13 | 2022-08-18 | Aptevo Res & Development Llc | Formulaciones para productos terapeuticos proteicos. |
JP2023512446A (ja) | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
WO2021151119A1 (en) * | 2020-01-23 | 2021-07-29 | Exuma Biotech Corp. | Chimeric antigen receptors to her2 and methods of use thereof |
CN115894703A (zh) | 2020-04-29 | 2023-04-04 | 特尼奥生物股份有限公司 | 具有经修饰重链恒定区的多特异性重链抗体 |
CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
CN115916825A (zh) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 与cd3和cd19结合的抗体 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
EP4255931A1 (en) | 2020-12-03 | 2023-10-11 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
US20220267438A1 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
BR112023019484A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 |
KR20240024819A (ko) | 2021-05-21 | 2024-02-26 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 단백질 치료제의 투약 요법 |
CN117980326A (zh) | 2021-07-14 | 2024-05-03 | 2赛文缇生物公司 | 与来自抗体的结合结构域融合的经工程化的t细胞受体 |
WO2023060180A1 (en) * | 2021-10-06 | 2023-04-13 | The Wistar Institute Of Anatomy And Biology | Novel immune cell engagers for immunotherapy |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
TW202406571A (zh) | 2022-04-13 | 2024-02-16 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
IT1271461B (it) * | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
AU6113396A (en) * | 1995-06-14 | 1997-01-15 | Regents Of The University Of California, The | Novel high affinity human antibodies to tumor antigens |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
JP4169478B2 (ja) * | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Cd19×cd3特異的ポリペプチドおよびその使用 |
CA2332331A1 (en) * | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
CN100497389C (zh) * | 2001-06-13 | 2009-06-10 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
ES2429112T3 (es) * | 2002-04-10 | 2013-11-13 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
US7615355B2 (en) * | 2002-04-22 | 2009-11-10 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
DK1673398T3 (da) * | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
US20050142133A1 (en) * | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
MXPA06009253A (es) * | 2004-02-16 | 2007-04-18 | Micromet Ag | Moleculas de enlace menos inmunogenicas. |
US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
BRPI0511782B8 (pt) | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
KR20070057839A (ko) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
AR057807A1 (es) | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
CA2625440C (en) * | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1945674A2 (en) * | 2005-11-03 | 2008-07-23 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
US9023356B2 (en) * | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
NZ580746A (en) * | 2007-04-03 | 2012-05-25 | Micromet Ag | Cross-species-specific bispecific binders |
JP2010524851A (ja) * | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
-
2008
- 2008-04-03 CA CA002682626A patent/CA2682626A1/en active Pending
- 2008-04-03 MX MX2009010611A patent/MX2009010611A/es active IP Right Grant
- 2008-04-03 CN CN2008800142255A patent/CN101675077B/zh active Active
- 2008-04-03 AU AU2008234019A patent/AU2008234019B2/en active Active
- 2008-04-03 KR KR1020097023017A patent/KR101626988B1/ko active IP Right Grant
- 2008-04-03 PL PL08735000T patent/PL2155788T3/pl unknown
- 2008-04-03 US US12/594,729 patent/US20100183615A1/en not_active Abandoned
- 2008-04-03 WO PCT/EP2008/002663 patent/WO2008119566A2/en active Application Filing
- 2008-04-03 EP EP08735000A patent/EP2155788B1/en not_active Revoked
-
2009
- 2009-10-01 IL IL201338A patent/IL201338A/en active IP Right Grant
- 2009-10-13 ZA ZA2009/07116A patent/ZA200907116B/en unknown
-
2010
- 2010-08-10 HK HK10107647.0A patent/HK1141299A1/xx not_active IP Right Cessation
-
2012
- 2012-02-29 US US13/408,363 patent/US20120244162A1/en not_active Abandoned
- 2012-09-26 HR HRP20120759AT patent/HRP20120759T1/hr unknown
-
2013
- 2013-10-22 JP JP2013218769A patent/JP6016747B2/ja active Active
-
2015
- 2015-11-20 US US14/947,902 patent/US20160152707A1/en not_active Abandoned
-
2019
- 2019-09-27 US US16/586,318 patent/US20200095319A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL201338A0 (en) | 2010-05-31 |
US20200095319A1 (en) | 2020-03-26 |
US20120244162A1 (en) | 2012-09-27 |
KR20100016199A (ko) | 2010-02-12 |
JP6016747B2 (ja) | 2016-10-26 |
PL2155788T3 (pl) | 2013-02-28 |
US20160152707A1 (en) | 2016-06-02 |
AU2008234019B2 (en) | 2014-05-29 |
WO2008119566A3 (en) | 2009-01-08 |
HRP20120759T1 (hr) | 2012-10-31 |
AU2008234019A1 (en) | 2008-10-09 |
HK1141299A1 (en) | 2010-11-05 |
EP2155788A2 (en) | 2010-02-24 |
CN101675077B (zh) | 2013-09-04 |
IL201338A (en) | 2015-05-31 |
WO2008119566A2 (en) | 2008-10-09 |
ZA200907116B (en) | 2011-03-30 |
KR101626988B1 (ko) | 2016-06-02 |
CA2682626A1 (en) | 2008-10-09 |
US20100183615A1 (en) | 2010-07-22 |
EP2155788B1 (en) | 2012-06-27 |
JP2014064568A (ja) | 2014-04-17 |
CN101675077A (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010611A (es) | Enlazadores biespecificos, especificos para especies. | |
MX2009010610A (es) | Dominio de enlace especifico de especies cruzadas. | |
WO2008119565A3 (en) | Cross-species-specific binding domain | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
WO2010037838A3 (en) | Cross-species-specific single domain bispecific single chain antibody | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
MX348360B (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
MX2011003502A (es) | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. | |
EP3539988A3 (en) | Monoclonal antibodies against her2 | |
WO2009068625A3 (en) | Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
MY156286A (en) | Human il-23 antigen binding proteins | |
WO2007067991A3 (en) | Human monoclonal antibodies to o8e | |
WO2021064137A3 (en) | Multi-specific binding proteins for cancer treatment | |
WO2005097184A3 (en) | Antibodies against nogo receptor | |
SG10201804151QA (en) | Anti-egfr antibodies and uses thereof | |
WO2012143524A3 (en) | Bispecific antibodies against her2 and cd3 | |
MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
MY177065A (en) | 4-1bb binding molecules | |
NZ717429A (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
WO2008076560A3 (en) | Human monoclonal antibodies to btla and methods of use | |
WO2010037837A3 (en) | Bispecific single chain antibodies with specificity for high molecular weight target antigens | |
MY162624A (en) | Antibodies directed to her-3 and uses thereof | |
WO2012009544A3 (en) | Domain insertion immunoglobulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |